Indaptus Therapeutics
Price & Volume
Stats
See more52W Range | $0.45-$3.10 |
Market Cap | $6.6M |
Shares Short | 52,408 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$1.61 |
News
See moreYahoo Finance • 24 days ago
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Yahoo Finance • 24 days ago
Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025
Yahoo Finance • last month
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments
Yahoo Finance • 2 months ago
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
About
CEO | Mr. Jeffrey A. Meckler J.D. |
CFO | Mr. Nir Sassi |
Address | Three Columbus Circle, New York, NY, United States, 10019 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 7 |
